Novartis AG (NVS)
NYSE: NVS · Real-Time Price · USD
111.68
+1.13 (1.02%)
At close: May 7, 2025, 4:00 PM
110.00
-1.68 (-1.50%)
After-hours: May 7, 2025, 4:35 PM EDT

Revenue by Product

Fiscal year is January - December.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2012 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2012 - 2019
Innovative Medicines
50.32B
Log In
Log In
Log In
Log In
Upgrade
Innovative Medicines Growth
11.58%
Log In
Log In
Log In
Log In
Upgrade
Sandoz
-
Log In
Log In
Log In
Log In
Upgrade
Sandoz Growth
-
Log In
Log In
Log In
Log In
Upgrade
Cardiovascular, Renal And Metabolic
8.58B
Log In
Log In
Log In
Log In
Upgrade
Cardiovascular, Renal And Metabolic Growth
34.21%
Log In
Log In
Log In
Log In
Upgrade
Immunology
9.29B
Log In
Log In
Log In
Log In
Upgrade
Immunology Growth
19.18%
Log In
Log In
Log In
Log In
Upgrade
Neuroscience
4.75B
Log In
Log In
Log In
Log In
Upgrade
Neuroscience Growth
30.13%
Log In
Log In
Log In
Log In
Upgrade
Oncology
14.74B
Log In
Log In
Log In
Log In
Upgrade
Oncology Growth
14.69%
Log In
Log In
Log In
Log In
Upgrade
Established Brands
12.96B
Log In
Log In
Log In
Log In
Upgrade
Established Brands Growth
-12.16%
Log In
Log In
Log In
Log In
Upgrade

EBIT by Product

Fiscal year is January - December.
Fiscal Year
FY 2023 FY 2022 FY 2021 FY 2020 2011 - 2018
Period Ending
Dec '23 Dec '22 Dec '21 Dec '20 2011 - 2018
Innovative Medicines Operating Profit
Log In
Log In
Log In
Log In
Upgrade
Innovative Medicines Operating Profit Growth
Log In
Log In
Log In
Log In
Upgrade
Sandoz Operating Profit
Log In
Log In
Log In
Log In
Upgrade
Sandoz Operating Profit Growth
Log In
Log In
Log In
Log In
Upgrade
Corporate Operating Profit
Log In
Log In
Log In
Log In
Upgrade
Corporate Operating Profit Growth
Log In
Log In
Log In
Log In
Upgrade

Gross Income by Product

Fiscal year is January - December.
Fiscal Year
FY 2023 FY 2022 FY 2021 FY 2020 2011 - 2018
Period Ending
Dec '23 Dec '22 Dec '21 Dec '20 2011 - 2018
Innovative Medicines Gross Profit
Log In
Log In
Log In
Log In
Upgrade
Innovative Medicines Gross Profit Growth
Log In
Log In
Log In
Log In
Upgrade
Sandoz Gross Profit
Log In
Log In
Log In
Log In
Upgrade
Sandoz Gross Profit Growth
Log In
Log In
Log In
Log In
Upgrade
Corporate Gross Profit
Log In
Log In
Log In
Log In
Upgrade
Corporate Gross Profit Growth
Log In
Log In
Log In
Log In
Upgrade

Other

Fiscal year is January - December.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2012 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2012 - 2019
United States Revenue (Post-Q2 2023 Reporting)
21.15B
Log In
Log In
Log In
Log In
Upgrade
United States Revenue (Post-Q2 2023 Reporting) Growth
17.75%
Log In
Log In
Log In
Log In
Upgrade
Europe Revenue (Post-Q2 2023 Reporting)
15.56B
Log In
Log In
Log In
Log In
Upgrade
Europe Revenue (Post-Q2 2023 Reporting) Growth
3.73%
Log In
Log In
Log In
Log In
Upgrade
Asia/Africa/Australasia Revenue (Post-Q2 2023 Reporting)
10.02B
Log In
Log In
Log In
Log In
Upgrade
Asia/Africa/Australasia Revenue (Post-Q2 2023 Reporting) Growth
7.66%
Log In
Log In
Log In
Log In
Upgrade
Canada and Latin America Revenue (Post-Q2 2023 Reporting)
3.59B
Log In
Log In
Log In
Log In
Upgrade
Canada and Latin America Revenue (Post-Q2 2023 Reporting) Growth
13.13%
Log In
Log In
Log In
Log In
Upgrade
Europe Revenue (Pre-Q3 2023 Reporting)
-
Log In
Log In
Log In
Log In
Upgrade
Europe Revenue (Pre-Q3 2023 Reporting) Growth
-
Log In
Log In
Log In
Log In
Upgrade
United States Revenue (Pre-Q3 2023 Reporting)
-
Log In
Log In
Log In
Log In
Upgrade
United States Revenue (Pre-Q3 2023 Reporting) Growth
-
Log In
Log In
Log In
Log In
Upgrade
Asia/Africa/Australasia Revenue (Pre-Q3 2023 Reporting)
-
Log In
Log In
Log In
Log In
Upgrade
Asia/Africa/Australasia Revenue (Pre-Q3 2023 Reporting) Growth
-
Log In
Log In
Log In
Log In
Upgrade
Canada and Latin America Revenue (Pre-Q3 2023 Reporting)
-
Log In
Log In
Log In
Log In
Upgrade
Canada and Latin America Revenue (Pre-Q3 2023 Reporting) Growth
-
Log In
Log In
Log In
Log In
Upgrade
Gilenya Revenue
552.00M
Log In
Log In
Log In
Log In
Upgrade
Gilenya Revenue Growth
-40.32%
Log In
Log In
Log In
Log In
Upgrade
Tasigna Revenue
1.67B
Log In
Log In
Log In
Log In
Upgrade
Tasigna Revenue Growth
-9.58%
Log In
Log In
Log In
Log In
Upgrade
Lucentis Revenue
1.04B
Log In
Log In
Log In
Log In
Upgrade
Lucentis Revenue Growth
-29.22%
Log In
Log In
Log In
Log In
Upgrade
Cosentyx Revenue
6.14B
Log In
Log In
Log In
Log In
Upgrade
Cosentyx Revenue Growth
23.31%
Log In
Log In
Log In
Log In
Upgrade
Entresto Revenue
7.82B
Log In
Log In
Log In
Log In
Upgrade
Entresto Revenue Growth
29.61%
Log In
Log In
Log In
Log In
Upgrade